Summary:
The BEACON Study is evaluating the efficacy, safety and tolerability of an investigational medicine (HZN-825) that may slow disease progression in participants with dcSSc.
Criteria:- be 18 - 75 at the time of consent
- been diagnosed with Systemic Sclerosis with first manifestation of symptoms within 6 years
- not diagnosed with cancer in the past 5 years (other than basal or squamous skin cancer)
- have skin involvement of the elbows or knees
Qualified Participants May Receive:
- 52 weeks of study medication during the trial at no cost
- Study medical care by Rheumatologist and Pulmonologist at no cost
- Compensation for participation up to $3,000
- Additional 52 weeks of "open-label" study medication at no cost